{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:59:47Z","timestamp":1794333587733,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2014R1A1A2053938"],"award-info":[{"award-number":["NRF-2014R1A1A2053938"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2013R1A1A2063440"],"award-info":[{"award-number":["2013R1A1A2063440"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R&D Convergence Program of the NST of the Republic of Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis is involved in both normal physiological and pathological conditions. Vascular endothelial growth factor (VEGF) is a major factor for promoting angiogenesis. The current anti-VEGF therapies have limited efficacy and significant adverse effects. To find novel targets of VEGFA for angiogenesis inhibition, we performed yeast two-hybrid screening and identified calpain-6 as a novel VEGFA-interaction partner and confirmed the endogenous VEGFA\u2013calpain-6 interaction in mammalian placenta. A domain mapping study revealed that the Gly321\u2013Asp500 domain in calpain-6 is required for the interaction with the C-terminus of the VEGFA protein. The functional significance of the VEGFA\u2013calpain-6 interaction was explored by assessing its effect on angiogenesis <jats:italic>in vitro<\/jats:italic>. Whereas forced overexpression of calpain-6 increased the secretion of the VEGF protein and tube formation, knockdown of calpain-6 expression abrogated the calpain-6-mediated VEGF secretion and tube formation in HUVECs. Consistent with the domain mapping result, overexpressing calpain-6 without the VEGFA-interacting domain III (Gly321\u2013Asp500) failed to increase the secretion of VEGF protein. Our results identify calpain-6, an unconventional non-proteolytic calpain, as a novel VEGFA-interacting protein and demonstrate that their interaction is necessary to enhance VEGF secretion. Thus, calpain-6 might be a potential molecular target for angiogenesis inhibition in many diseases.<\/jats:p>","DOI":"10.1038\/s41598-019-52364-6","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T11:08:43Z","timestamp":1572520123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Non-proteolytic calpain-6 interacts with VEGFA and promotes angiogenesis by increasing VEGF secretion"],"prefix":"10.1038","volume":"9","author":[{"given":"Mijung","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bae","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaeyeun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungsook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"52364_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/386671a0","volume":"386","author":"W Risau","year":"1997","unstructured":"Risau, W. Mechanisms of angiogenesis. Nature 386, 671\u2013674 (1997).","journal-title":"Nature"},{"key":"52364_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1054\/bjoc.1999.0991","volume":"82","author":"MK Oehler","year":"2000","unstructured":"Oehler, M. K. & Bicknell, R. The promise of anti-angiogenic cancer therapy. Br. J. Cancer 82, 749\u2013752 (2000).","journal-title":"Br. J. Cancer"},{"key":"52364_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359\u2013371 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"52364_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36394-0","volume":"8","author":"M Farzaneh Behelgardi","year":"2018","unstructured":"Farzaneh Behelgardi, M., Zahri, S., Mashayekhi, F., Mansouri, K. & Asghari, S. M. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1\/-2 driven angiogenesis, tumor growth and metastasis. Sci. Rep. 8, 17924 (2018).","journal-title":"Sci. Rep."},{"key":"52364_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1006094117427","volume":"17","author":"L Witte","year":"1998","unstructured":"Witte, L. et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1\/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17, 155\u2013161 (1998).","journal-title":"Cancer Metastasis Rev."},{"key":"52364_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1021540120521","volume":"5","author":"W Zhang","year":"2002","unstructured":"Zhang, W., Ran, S., Sambade, M., Huang, X. & Thorpe, P. E. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR\/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5, 35\u201344 (2002).","journal-title":"Angiogenesis"},{"key":"52364_CR7","first-page":"12","volume":"91","author":"C Hopirtean","year":"2018","unstructured":"Hopirtean, C. & Nagy, V. Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. Clujul Med 91, 12\u201317 (2018).","journal-title":"Clujul Med"},{"key":"52364_CR8","first-page":"XE01","volume":"9","author":"L Yadav","year":"2015","unstructured":"Yadav, L., Puri, N., Rastogi, V., Satpute, P. & Sharma, V. Tumour Angiogenesis and Angiogenic Inhibitors: A Review. J Clin Diagn Res 9, XE01\u2013XE05 (2015).","journal-title":"J Clin Diagn Res"},{"key":"52364_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada, C. C., Maldonado, A. & Mallipattu, S. K. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J. Am. Soc. Nephrol. 30, 187\u2013200 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"52364_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/bju.13070","volume":"116","author":"AP Fay","year":"2015","unstructured":"Fay, A. P. & Bellmunt, J. Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? BJU Int. 116, 500\u2013501 (2015).","journal-title":"BJU Int."},{"key":"52364_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534\u20131540 (2012).","journal-title":"J. Clin. Oncol."},{"key":"52364_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh, L. & Welsh, M. VEGFA and tumour angiogenesis. J. Intern. Med. 273, 114\u2013127 (2013).","journal-title":"J. Intern. Med."},{"key":"52364_CR13","first-page":"199","volume":"53","author":"MI Costache","year":"2015","unstructured":"Costache, M. I. et al. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Rom. J. Intern. Med. 53, 199\u2013208 (2015).","journal-title":"Rom. J. Intern. Med."},{"key":"52364_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","volume":"330","author":"A Lapeyre-Prost","year":"2017","unstructured":"Lapeyre-Prost, A. et al. Immunomodulatory Activity of VEGF in Cancer. Int. Rev. Cell Mol. Biol. 330, 295\u2013342 (2017).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"52364_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","volume":"102","author":"N Murukesh","year":"2010","unstructured":"Murukesh, N., Dive, C. & Jayson, G. C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8\u201318 (2010).","journal-title":"Br. J. Cancer"},{"key":"52364_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2018.03.019","volume":"482","author":"V Dalal","year":"2018","unstructured":"Dalal, V. et al. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin. Chim. Acta 482, 27\u201332 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"52364_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0304-3835(97)00350-9","volume":"121","author":"EM Hartenbach","year":"1997","unstructured":"Hartenbach, E. M. et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 121, 169\u2013175 (1997).","journal-title":"Cancer Lett."},{"key":"52364_CR18","first-page":"1973","volume":"24","author":"L Li","year":"2004","unstructured":"Li, L. et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24, 1973\u20131979 (2004).","journal-title":"Anticancer Res."},{"key":"52364_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P. & Heinemann, V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur. J. Cancer 70, 87\u201398 (2017).","journal-title":"Eur. J. Cancer"},{"key":"52364_CR20","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak, H. F. Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368\u20134380 (2002).","journal-title":"J. Clin. Oncol."},{"key":"52364_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011\u20131027 (2005).","journal-title":"J. Clin. Oncol."},{"key":"52364_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129\u20131136 (2008).","journal-title":"N. Engl. J. Med."},{"key":"52364_CR23","doi-asserted-by":"crossref","unstructured":"Rajabi, M. & Mousa, S. A. The Role of Angiogenesis in Cancer Treatment. Biomedicines 5 (2017).","DOI":"10.3390\/biomedicines5020034"},{"key":"52364_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2018.06.003","volume":"191","author":"S Bousseau","year":"2018","unstructured":"Bousseau, S. et al. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis. Pharmacol. Ther. 191, 92\u2013122 (2018).","journal-title":"Pharmacol. Ther."},{"key":"52364_CR25","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1038\/s41388-018-0271-7","volume":"37","author":"R Imamaki","year":"2018","unstructured":"Imamaki, R. et al. Glycosylation controls cooperative PECAM-VEGFR2-beta3 integrin functions at the endothelial surface for tumor angiogenesis. Oncogene 37, 4287\u20134299 (2018).","journal-title":"Oncogene"},{"key":"52364_CR26","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1002\/jcp.27649","volume":"234","author":"J Chen","year":"2019","unstructured":"Chen, J., Wu, Y., Zhang, L., Fang, X. & Hu, X. Evidence for calpains in cancer metastasis. J. Cell. Physiol. 234, 8233\u20138240 (2019).","journal-title":"J. Cell. Physiol."},{"key":"52364_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jmb.2004.08.073","volume":"343","author":"CM Hosfield","year":"2004","unstructured":"Hosfield, C. M., Elce, J. S. & Jia, Z. Activation of calpain by Ca2+: roles of the large subunit N-terminal and domain III-IV linker peptides. J. Mol. Biol. 343, 1049\u20131053 (2004).","journal-title":"J. Mol. Biol."},{"key":"52364_CR28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.str.2003.11.007","volume":"11","author":"GP Pal","year":"2003","unstructured":"Pal, G. P., De Veyra, T., Elce, J. S. & Jia, Z. Crystal structure of a micro-like calpain reveals a partially activated conformation with low Ca2+ requirement. Structure 11, 1521\u20131526 (2003).","journal-title":"Structure"},{"key":"52364_CR29","doi-asserted-by":"publisher","first-page":"7404","DOI":"10.1074\/jbc.M007352200","volume":"276","author":"CM Hosfield","year":"2001","unstructured":"Hosfield, C. M., Moldoveanu, T., Davies, P. L., Elce, J. S. & Jia, Z. Calpain mutants with increased Ca2+ sensitivity and implications for the role of the C(2)-like domain. J. Biol. Chem. 276, 7404\u20137407 (2001).","journal-title":"J. Biol. Chem."},{"key":"52364_CR30","doi-asserted-by":"publisher","first-page":"16336","DOI":"10.1074\/jbc.M208657200","volume":"278","author":"S Gil-Parrado","year":"2003","unstructured":"Gil-Parrado, S. et al. Subcellular localization and in vivo subunit interactions of ubiquitous mu-calpain. J. Biol. Chem. 278, 16336\u201316346 (2003).","journal-title":"J. Biol. Chem."},{"key":"52364_CR31","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1128\/MCB.00992-06","volume":"27","author":"K Tonami","year":"2007","unstructured":"Tonami, K. et al. Calpain 6 is involved in microtubule stabilization and cytoskeletal organization. Mol. Cell. Biol. 27, 2548\u20132561 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"52364_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1242\/jcs.072561","volume":"124","author":"K Tonami","year":"2011","unstructured":"Tonami, K. et al. Calpain-6, a microtubule-stabilizing protein, regulates Rac1 activity and cell motility through interaction with GEF-H1. J. Cell Sci. 124, 1214\u20131223 (2011).","journal-title":"J. Cell Sci."},{"key":"52364_CR33","doi-asserted-by":"publisher","first-page":"e1003668","DOI":"10.1371\/journal.pgen.1003668","volume":"9","author":"K Tonami","year":"2013","unstructured":"Tonami, K. et al. Calpain-6 deficiency promotes skeletal muscle development and regeneration. PLoS Genet. 9, e1003668 (2013).","journal-title":"PLoS Genet."},{"key":"52364_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/geno.1997.4870","volume":"45","author":"N Dear","year":"1997","unstructured":"Dear, N., Matena, K., Vingron, M. & Boehm, T. A new subfamily of vertebrate calpains lacking a calmodulin-like domain: implications for calpain regulation and evolution. Genomics 45, 175\u2013184 (1997).","journal-title":"Genomics"},{"key":"52364_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd.2016.212","volume":"15","author":"Y Ono","year":"2016","unstructured":"Ono, Y., Saido, T. C. & Sorimachi, H. Calpain research for drug discovery: challenges and potential. Nat. Rev. Drug Discov. 15, 854\u2013876 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52364_CR36","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1096\/fj.05-5354com","volume":"20","author":"Y Su","year":"2006","unstructured":"Su, Y., Cui, Z., Li, Z. & Block, E. R. Calpain-2 regulation of VEGF-mediated angiogenesis. FASEB J. 20, 1443\u20131451 (2006).","journal-title":"FASEB J."},{"key":"52364_CR37","doi-asserted-by":"crossref","unstructured":"Andrique, C. et al. Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence. JCI Insight 3 (2018).","DOI":"10.1172\/jci.insight.121225"},{"key":"52364_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1525-1438.2006.00756.x","volume":"17","author":"SJ Lee","year":"2007","unstructured":"Lee, S. J. et al. Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. Int. J. Gynecol. Cancer 17, 248\u2013253 (2007).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"52364_CR39","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/ijc.26246","volume":"130","author":"A Marion","year":"2012","unstructured":"Marion, A. et al. Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma. Int. J. Cancer 130, 2514\u20132525 (2012).","journal-title":"Int. J. Cancer"},{"key":"52364_CR40","first-page":"859","volume":"19","author":"SJ Lee","year":"2008","unstructured":"Lee, S. J., Kim, B. G., Choi, Y. L. & Lee, J. W. Increased expression of calpain 6 during the progression of uterine cervical neoplasia: immunohistochemical analysis. Oncol. Rep. 19, 859\u2013863 (2008).","journal-title":"Oncol. Rep."},{"key":"52364_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jog.13172","volume":"43","author":"L Xia","year":"2017","unstructured":"Xia, L., Liu, Y., Fu, Y., Dongye, S. & Wang, D. Integrated analysis reveals candidate mRNA and their potential roles in uterine leiomyomas. J. Obstet. Gynaecol. Res. 43, 149\u2013156 (2017).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"52364_CR42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00424-016-1933-3","volume":"469","author":"K Sakuma","year":"2017","unstructured":"Sakuma, K., Aoi, W. & Yamaguchi, A. Molecular mechanism of sarcopenia and cachexia: recent research advances. Pflugers Arch. 469, 573\u2013591 (2017).","journal-title":"Pflugers Arch."},{"key":"52364_CR43","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.18632\/oncotarget.4821","volume":"7","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1. Oncotarget 7, 13491\u201313501 (2016).","journal-title":"Oncotarget"},{"key":"52364_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.canlet.2008.06.020","volume":"271","author":"SB Rho","year":"2008","unstructured":"Rho, S. B., Byun, H. J., Park, S. Y. & Chun, T. Calpain 6 supports tumorigenesis by inhibiting apoptosis and facilitating angiogenesis. Cancer Lett. 271, 306\u2013313 (2008).","journal-title":"Cancer Lett."},{"key":"52364_CR45","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3892\/ol.2017.5687","volume":"13","author":"Y Xiang","year":"2017","unstructured":"Xiang, Y. et al. Decreased calpain 6 expression is associated with tumorigenesis and poor prognosis in HNSCC. Oncol. Lett. 13, 2237\u20132243 (2017).","journal-title":"Oncol. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52364-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:17:50Z","timestamp":1671290270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52364-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52364"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52364-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15771"}}